$2.31
-0.78 (-25.24%)
Open$2.98
Previous Close$3.09
Day High$2.99
Day Low$2.23
52W High$55.92
52W Low$2.18
Volume—
Avg Volume13.24M
Market Cap2.02M
P/E Ratio—
EPS$-934.89
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,827.7% upside
Current
$2.31
$2.31
Target
$44.53
$44.53
$37.12
$44.53 avg
$63.68
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.28M | 1.20M | 1.36M |
| Net Income | 141.5K | 105.1K | 144.5K |
| Profit Margin | 11.1% | 8.8% | 10.6% |
| EBITDA | 291.4K | 241.4K | 275.9K |
| Free Cash Flow | 83.4K | 101.2K | 72.7K |
| Rev Growth | +11.3% | +13.4% | -9.5% |
| Debt/Equity | 0.31 | 0.28 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |